Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Authors: Xochelli Aliki , Baliakas Panagiotis , Kavakiotis Ioannis , Agathangelidis Andreas , Sutton Lesley-Ann , Minga Eva , Ntoufa Stavroula , Tausch Eugen , Yan Xiao-Jie , Shanafelt Tait , Plevova Karla , Boudjogra Myriam , Rossi Davide , Davis Zadie , Navarro Alba , Sandberg Yorick , Vojdeman Fie Juhl , Scarfo Lydia , Stavroyianni Niki , Sudarikov Andrey , Veronese Silvio , Tzenou Tatiana , Karan-Djurasevic Teodora , Catherwood Mark , Kienle Dirk , Chatzouli Maria , Facco Monica , Bahlo Jasmin , Pott Christiane , Pedersen Lone Bredo , Mansouri Larry , Smedby Karin E. , Chu Charles C. , Giudicelli Véronique , Lefranc Marie-Paule , Panagiotidis Panagiotis , Juliusson Gunnar , Anagnostopoulos Achilles , Vlahavas Ioannis , Antic Darko , Trentin Livio , Montillo Marco , Niemann Carsten , Döhner Hartmut , Langerak Anton W. , Pospisilova Sarka , Hallek Michael , Campo Elias , Chiorazzi Nicholas , Maglaveras Nikos , Oscier David , Gaidano Gianluca , Jelinek Diane F. , Stilgenbauer Stephan , Chouvarda Ioanna , Darzentas Nikos , Belessi Chrysoula , Davi Frederic , Hadzidimitriou Anastasia , Rosenquist Richard , Ghia Paolo , Stamatopoulos Kostas 
Published: May 2017

AbstractPurpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication.Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34–expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes.Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P &lt; 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively).Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 23(17); 5292–301. ©2017 AACR.